Latest Breaking News On - Antonioc arrieta - Page 1 : comparemela.com

FDA Approves Isavuconazonium Sulfate to Treat Invasive Aspergillosis and Invasive Mucormycotic

The approval marks isavuconazonium sulfate as the only granted azole antifungal therapy for pediatric individuals AI and IM that are as young as 1 years old.

Lynn fenicchiaAntonioc arrietaAstellas pharma us incChildren health of orangeAstellas pharmaPediatric infectious diseaseOrange countySpecialties business unit

FDA Approves Expanded Use of CRESEMBA® (isavuconazonium sulfate) in Children with Invasive Aspergillosis and Invasive Mucormycosis

/PRNewswire/ Astellas Pharma US, Inc. (President: Mark Reisenauer, "Astellas") today announced that the U.S. Food and Drug Administration (FDA) has approved.

United statesStevens johnsonAntonioc arrietaMark reisenauerLynn fenicchiaDrug administrationPrnewswire astellas pharma us incBasilea pharmaceutica international ltdAstellas pharma us incChildren health of orangeAstellas pharma incPediatric infectious diseaseSpecialties business unitMedical mycologyInvasive aspergillosisSafety information

FDA Approves Expanded Use of CRESEMBA® (isavuconazonium sulfate) in Children with Invasive Aspergillosis and Invasive Mucormycosis

FDA Approves Expanded Use of CRESEMBA® (isavuconazonium sulfate) in Children with Invasive Aspergillosis and Invasive Mucormycosis
kptv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kptv.com Daily Mail and Mail on Sunday newspapers.

United statesLynn fenicchiaStevens johnsonAntonioc arrietaMark reisenauerAstellas pharma us incChildren health of orangeDrug administrationAstellas pharma incBasilea pharmaceutica international ltdPrnewswire astellas pharma us incPediatric infectious diseaseSpecialties business unitMedical mycologyInvasive aspergillosisSafety information